Last updated: May 24, 2026
Ripretinib supply is driven by (1) the drug’s proprietary tosylate-formulation manufacturing chain and (2) the upstream synthesis and purification of ripretinib API. Publicly available disclosures are not sufficient to name specific, current suppliers for ripretinib drug product, ripretinib API, or packaging/labeling contractors with enough completeness for business or litigation-grade use.
Which companies supply ripretinib (Qinlock) drug product and finished dosage forms?
No complete, authoritative supplier roster for ripretinib drug product is available from the sources required for a complete answer.
What dosage forms are supplied under ripretinib’s brand chain?
Ripretinib is marketed as tablets (brand: Qinlock). Supplier-level detail for tablet manufacturing, coating, packaging, and release testing is not verifiable from available public records at the level needed to identify specific contractors.
What manufacturing sites are used for Qinlock tablets?
Manufacturing-site assignments (drug product) and associated contract manufacturers are not sufficiently documented in accessible public sources to support supplier identification.
Who manufactures ripretinib API and intermediates?
No complete, authoritative list of ripretinib API suppliers and intermediate manufacturers is available from public disclosures that support exact naming.
How does ripretinib API supply affect availability?
API sourcing constraints typically translate into drug-product allocation risk when:
- there are single-source steps in chemical synthesis,
- purification capacity is limited,
- regulatory batch release timelines are tight,
- there are stability or impurity-control bottlenecks.
Supplier-specific evidence is not available to tie these risks to named API manufacturers for ripretinib.
Are there contract manufacturing organizations (CMOs) for ripretinib tablets?
No supplier-specific CMO roster for ripretinib tablets is supported by sufficiently complete public documentation.
What types of CMOs would be involved in ripretinib tablet supply?
A ripretinib tablet supply chain commonly spans:
- formulation development scale-up (pre-formulation, granulation, coating),
- tablet manufacturing and blending,
- packaging and distribution logistics,
- quality control, stability testing, and regulatory release.
No verified names of contractors can be provided.
What information in regulatory filings can identify ripretinib suppliers?
Routinely, supplier identifiers can appear via:
- FDA CDER drug master file (DMF) linkages,
- manufacturing-site listings tied to the approved application,
- inspectional observations or establishment inspections,
- labeling and regulatory correspondence.
No accessible set of filings is available here with enough coverage to map ripretinib to specific suppliers.
How can ripretinib supplier choices impact pricing and continuity of supply?
When supply is concentrated, pricing and continuity often track:
- API lead times,
- batch release schedule performance,
- availability of key excipients and coating systems,
- internal quality systems and impurity controls.
Supplier-specific quantification and named-company sourcing evidence are not available.
What licensing or supply agreements affect ripretinib sourcing?
No licensing or supply agreement details identifying named ripretinib suppliers are available in the public record set required for a complete analysis.
Which regions have the highest ripretinib supply-chain concentration?
No region-by-region supplier map can be produced from available data.
Does ripretinib have multiple manufacturing sites across geographies?
Publicly accessible establishment-by-establishment assignments are not available in a way that supports a supplier-grade answer.
What generic or biosimilar-related activities could change ripretinib supply?
Ripretinib is a small-molecule targeted therapy. Generic entry could alter supply dynamics, but the present supplier landscape cannot be anchored to specific companies from public records in this dataset.
Key Takeaways
- A complete, business-actionable list of ripretinib suppliers (API manufacturers, drug-product CMOs, and packaging/release contractors) cannot be produced from available public documentation with sufficient specificity.
- Supplier identification for ripretinib requires manufacturing-site and DMF-level traceability that is not available in the current dataset.
- Supply-chain continuity risk for ripretinib is typically dominated by API synthesis and drug-product tablet manufacturing bottlenecks, but named-company details are not supported.
FAQs
- What is Qinlock’s (ripretinib) standard tablet strength and how does that affect sourcing?
- Where in FDA submissions do ripretinib manufacturing sites and supplier linkages typically appear?
- How do API impurity specifications constrain contract API sourcing for small-molecule kinase inhibitors like ripretinib?
- What are the most common manufacturing steps where ripretinib supply bottlenecks occur (synthesis, purification, blending, coating)?
- How should procurement teams validate ripretinib suppliers for regulatory compliance (GMP, batch release, stability, CoA traceability)?
References
- None (no qualifying public supplier-identifying sources were provided in the current dataset).
